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P2X receptors are ATP-gated cation channels that mediate fast excitatory transmission in diverse regions of the brain and spinal
cord. Several P2X receptor subtypes, including P2X7, have the unusual property of changing their ion selectivity during prolonged
exposure to ATP, which results in a channel pore permeable to molecules as large as 900 daltons. The P2X7 receptor was originally
described in cells of hematopoietic origin, and mediates the inﬂux of Ca
2+ and Na
+ and Ca
2+ and Na
+ ions as well as the release
of proinﬂammatory cytokines. P2X7 receptors may aﬀect neuronal cell death through their ability to regulate the processing
and release of interleukin-1β, a key mediator in neurodegeneration, chronic inﬂammation, and chronic pain. Activation of
P2X7, a key mediator in neurodegeneration, chronic inﬂammation, and chronic pain. Activation of P2X7 r e c e p t o r sp r o v i d e sa n
inﬂammatory stimulus,and P2X7 receptor-deﬁcient mice have substantially attenuated inﬂammatory responses, including models
of neuropathic and chronic inﬂammatory pain. Moreover, P2X7 receptor activity, by regulating the release of proinﬂammatory
cytokines, may be involved in the pathophysiology of depression. Apoptotic cell death occurs in a number of vascular diseases,
including atherosclerosis, restenosis, and hypertension, and may be linked to the release of ATP from endothelial cells, P2X7
receptor activation, proinﬂammatory cytokine production, and endothelial cell apoptosis. In this context, the P2X7 receptor may
be viewed as a gateway of communication between the nervous, immune, and cardiovascular systems.
Copyright © 2009 Stephen D. Skaper et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The role of extracellular ATP and purinoceptors in cytokine
regulationandneurologicaldisordersisthefocusofarapidly
expanding area of research. ATP can act as a neurotransmit-
ter, while the presence of the purinergic receptor subclass
P2X7 on immune cells suggests that it also regulates immune
functionandinﬂammatoryresponses.Inaddition,activation
of this receptor has dramatic cytotoxic properties which,
together with its ability to regulate cytokine production and
release, propose that it can act as an important regulator of
cell death in response to pathological insults in both nervous
and other (e.g., cardiovascular) tissues.
Neurodegenerationistheunderlyingbasisofmanydisor-
dersincludingcerebralischemia,braintrauma,multiplescle-
rosis, Parkinson’s, Alzheimer’s, and Huntington’s diseases.
Neuroinﬂammation in disorders such as Alzheimer’s disease
(AD)haspreviouslybeenviewedasanepiphenomenon,with
inﬂammation occurring when damaged neurons provoke
an activation response from glia. Accumulating evidence
now challenges this perspective and points to a more active
role of neuroinﬂammation in pathophysiology onset and
progression. In the central nervous system (CNS), glial cells
(microglia, astroglia, and oligodendroglia) not only serve
supportive and nutritive roles for neurons but also in the
healthy brain often respond to stress and insults by tran-
sientlyupregulatinginﬂammatoryprocesses.Theseprocesses
are kept in check by other endogenous anti-inﬂammatory
andneuroprotectiveresponsesthatreturnthebraintohome-
ostasis. Otherwise “normal” glial functions can sometimes
result in a more severe and chronic neuroinﬂammatory
cyclethatactuallypromotesorpropagatesneurodegenerative
disease [1]. The delicate balance in this homeostasis can be
disturbed, resulting in disease or exacerbation of initiating
factors that result in disease (i.e., the neuroinﬂammation
hypothesis) (Figure 1)[ 2].
Clinical evidence in support of neuroinﬂammation as a
pharmacological target for chronic neurodegenerative dis-
eases, such as AD, comes from epidemiological and genetic
linkage data. For example, long-term use of nonsteroidal2 Cardiovascular Psychiatry and Neurology
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Figure 1: The inﬂammatory cycle and neurodegeneration: Alzheimer’s disease as a case in point. In Alzheimer’s disease, the
neuroinﬂammatory cycle is characterized by sustained activation of microglia and astrocytes in response to activating stimuli, in particular,
amyloid beta (Aβ). Glia proinﬂammatory responses activated by Aβ include induction of cytokines (TNF-α,I L - 1 β, S100β), chemokines
(macrophage inﬂammatory proteins-1α, β:M I P - 1 α,M I P - 1 β), and oxidative stress-related molecules (nitric oxide, NO), which can cause
neuronal cell dysfunction and/or death and can further propagate the inﬂammatory response.
anti-inﬂammatory drugs is correlated with a protective
eﬀe c ta g a i n s tA D[ 3], and certain polymorphisms in the
genes for proinﬂammation mediators are associated with
increased risk [4]. Postmortem brain tissue from patients
with AD has expressed an array of inﬂammatory mediators,
including cytokines and chemokines in those regions most
aﬀected in the disorder [5]. Neuroinﬂammation has been
documented also in the aﬀected brain regions of individuals
suﬀering from Parkinson’s disease, multiple sclerosis, human
immunodeﬁciency virus type 1-associated dementia, and
various prion diseases [6–9], as well as cerebral ischemia
[10], spinal cord injury [11], and traumatic brain injury
[12]. The ability of P2X7 receptor activation to regulate
cytokine production and cellular vitality has implications
for other neurological disorders, for example, pain and
depression, as well as within the cardiovascular system.
Collectively these observations propose that excessive P2X7
receptor activation on both glia and vascular cells constitutes
a viable target for the discovery and development of novel
disease therapeutics. This review will discuss the current
biology and cellular signaling pathways of P2X7 receptor
function, as well as insights into the role for this receptor in
neurological/psychiatric and cardiovascular diseases, and the
therapeutic potential of P2X7 receptor antagonism.
2. P2X7 Receptor Biology
Virtually all cell types express plasma membrane receptors
for extracellular nucleotides, named P2 receptors. Presently,
15 members have been cloned and are classiﬁed into two
subfamilies: the G protein-coupled P2Y receptors and P2X
receptors [13,14].P2XreceptorsfunctionasATP-gatednon-
selective cationic channels permeable to Na+,K +,a n dC a 2+
[15]. The ability of P2X receptors to act as direct conduits
for Ca2+ inﬂux or indirect activators of voltage-gated Ca2+
channels underlies their multiple roles in Ca2+-based signal-
ing responses in those tissues. The channels are oligomeric
complexes composed of protein subunits encoded by seven
diﬀerentP2Xreceptorgenes(P2X1 throughP2X7)expressed
inmammalianandothervertebrategenomes.Theminimum
stoichiometric conformation of the P2X7 receptor channel
appears to be a trimer [13, 16]. Whether pore formation
results from intrinsic dilation of the channel [13]o rP 2 X 7
receptor-mediated downstream signaling remains to be fully
resolved.
All functional P2X receptor subtypes display a very high
selectivity for ATP over other physiological nucleotides [16].
The P2X7 receptor is unusual among the P2X receptor
family in that sustained activation by extracellular ATP
causes the formation of a reversible plasma membrane pore
permeable to hydrophilic solutes up to 900Da [13]. This
property is likely due to the receptor’s extended carboxy
terminal domain [17]. The P2X7 receptor activates a diverse
range of cellular responses including phospholipase A2,
phospholipaseD,mitogen-activatedproteinkinase(MAPK),
and nuclear factor-kappa B (NF-κB) (Figure 2)[ 13].
P2X7 receptors are selectively expressed on cells of
hematopoietic lineage including mast cells, erythrocytes,
monocytes, peripheral macrophages, dendritic cells, T-
and B-lymphocytes, and epidermal Langerhans cells [13].
Within the CNS, functional P2X7 receptors are localized
on microglia and Schwann cells as well as on astrocytes
[19, 20]. The existence of functional P2X7 receptors on
peripheral or central neurons remains controversial owing to
the poor selectivity of both antibodies and ligands targeting
the rat P2X7 receptor [21]. In rat peripheral sensory gangliaCardiovascular Psychiatry and Neurology 3
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Figure 2: Structure and signaling functions of the P2X7 receptor. (a) Each functional P2X7 receptor is a trimer [18], with the three protein
subunits arranged around a cation-permeable channel pore. The subunits all share a common topology, possessing two plasma membrane
spanning domains (TM1 and TM2), a large extracellular loop with the ATP binding site, and containing 10 similarly spaced cysteines and
glycosylation sites, and intracellular carboxyl and amino termini. (b) Brief ATP activation (<10 seconds) of the P2X7 receptor results in
rapid and reversible channel opening that is permeable to Na
+,K
+,a n dC a
2+. Acute receptor activation also triggers a series of cellular
responses, such as depolarization, degranulation, and membrane blebbing, along with signaling cascades (see Figure 3 for further details).
(c)Continuedstimulationresultsintheformationofalargerplasmamembranepore,whichfacilitatestheuptakeofcationicmoleculesupto
900Da (including ethidium bromide, which is frequently used as a tool to measure channel permeability, based on its property of generating
a ﬂuorescent signal upon DNA binding). Further activation of the receptor in some cell types results in the induction of apoptosis/cell lysis.
ATP-induced increase in IL-1β release is mediated mainly through the activation of IL-1β converting enzyme (also known as caspase-1).
Activation of the P2X7 receptor triggers the eﬄux of K
+ from cells which in turn activates IL-1 converting enzyme, leading to cleavage of
pro-IL-1β to mature IL-1β and release from the cell.
(dorsal root), P2X7 receptors appear to be selectively local-
ized on glial cells, but not neurons [22]. The best character-
ized activity of the P2X7 receptor is its role in interleukin-1β
(IL-1β) release from macrophages and microglia that have
been primed with substances such as bacterial endotoxin
(lipopolysaccharide,LPS)[23].ProtractedactivationofP2X7
receptors in some cell types results in the induction of
apoptosis [13, 24]. However, the physiological signiﬁcance of
this “highly stimulated” state of the P2X7 receptor is unclear.
The only known physiological activator of the P2X7
receptor is ATP. It is remarkable that activation of the P2X7
receptor requires near millimolar concentrations of ATP
(EC50 ∼ = 300μM). Since the cytoplasmic ATP concentration
isinthemillimolarrange,acutecellinjuryordeathwillcause
massive ATP release into the extracellular milieu. Indeed,
activated immune cells [25], macrophages [26], microglia
[27], platelets [28], and dying cells may release high concen-
trations of nucleotide di- and tri-phosphates into the extra-
cellularspace [29].ExtracellularATPconcentrationsincrease
signiﬁcantlyunderinﬂammatoryconditionsinvivo[30]and
in response to tissue trauma [31], suggesting that ATP levels
suﬃcient to activate the P2X7 receptor may be reached in
the pericellular space [28]. In addition, proinﬂammatory
cytokines and bacterial products up-regulate P2X7 receptor
expression and increase its sensitivity to extracellular ATP
[32, 33].
Deletion of P2X7 abolishes the ability of extracellular
ATP to induce IL-1β release from isolated macrophages
[34]. P2X7 receptor-deﬁcient mice are protected against
symptom development and cartilage destruction in anti-
collagen antibody-induced arthritis [35]. Disruption of the
P2X7 receptor gene abolishes chronic inﬂammatory and
neuropathic pain [36], and may play a role in the patho-
physiology of AD [37]. Recent studies suggest a link between
the P2X7 receptor gene and both neuropsychiatric [38]a n d
cardiovascular diseases [39]. These topics will be covered in
detail in later sections.
3. P2X7 Receptor Signaling
In macrophages/monocytes, P2X7 receptor stimulation
rapidly activates c-Jun N-terminal kinases 1 and 2 (JNK-
1/2) [40], extracellular signal-regulated kinase (ERK-1/2),4 Cardiovascular Psychiatry and Neurology
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Figure 3: Schematic depiction of the signal transduction events occurring in microglia following P2X7 receptor activation. Extracellular
calcium inﬂux triggered by activation of ionotropic P2X7 receptors leads to activation of calcineurin and dephosphorylation/activation of
NFAT (nuclear factor of activated T cells). P2X7 receptor activation also results in activation of phospholipases A2 and D (PLA2,P L D ) ,
as well as tyrosine phosphorylation (P-Tyr) and activation of mitogen-activated protein kinase (MAPK) pathway proteins (MAPK kinase,
MEK; extracellular signal-regulated kinase, ERK). The latter can then inﬂuence the activity of transcription factors like NF-κB (nuclear
factor-κB), CREB (cyclic AMP response element (CRE)-binding protein), and AP-1 (activator protein-1) which upregulate expression of
pro-inﬂammatory genes, such as cyclooxgenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). Activation of P2X7 receptors also
leads to p38 MAPK activation with consequent phosphorylation/activation of CREB. Broken lines indicate multistep pathways.
and p38 MAPK [41]. The P2X7 receptor agonist 2 ,3  -O-(4-
benzoyl-benzoyl)ATP (BzATP) activates the same pathways
in mouse N9 microglia [42], and increases the nuclear
translocation of NF-κB in mouse BV-2 microglia [42].
Dephosphorylation of NFAT (nuclear factor of activated T
cells) by calcineurin exposes a nuclear localization sequence,
permitting nuclear translocation and transcriptional acti-
vation [43]. In N9 cells, ATP activates NFAT via the
P2X7 receptors in a calcineurin-dependent fashion [44].
The cyclic AMP response element- (CRE-) binding protein
(CREB), a member of the ATF-1 (activating transcription
factor 1) family of transcription factors, is involved in
cytokine gene regulation [45]. P2X7 receptor-dependent
induction of CREB and ATF-1 phosphorylation occurs in
BV-2 cells via an MAPK kinase (MEK)/ERK-dependent
pathway [42]. Activation of activator protein-1 (AP-1) is
another transcription factor associated with regulation of
inﬂammatory genes [46]. Multiple members of the c-Fos
and c-Jun families dimerize to form AP-1. In serum-starved
Jurkat T-cells, activation of P2X7 receptors induced AP-1
DNA binding activity as a result of increased c-Jun and
c-Fos expression [47]. ATP treatment also increased the
phosphorylation of ERK-1/2 and JNK-1/2, but not p38
MAPK, providing a potential mechanism for these eﬀects
(Figure 3).
Stimulation of P2X7 receptors increases protein tyrosine
phosphorylation [48, 49] ultimately leading to MAPK path-
way activation. Many events downstream of P2X7 receptor
activation are dependent upon extracellular calcium inﬂux
[13,44],andactivationofMAPKpathwaysbyP2X7 receptors
may involve calcium signaling. In RAW 264.7 macrophages,
the calcium-dependent kinase Pyk2, which facilitates Ras
activation, is tyrosine phosphorylated in response to treat-
ment with BzATP [48, 50], potentially linking calcium
ﬂuxes, Ras activation, and MAPK pathways with P2X7
receptors. P2X7 receptors also induce the activation of
other small molecular weight G-proteins. For example,
the Rho/p38 pathway may be involved in the shedding
of IL-1β-containing vesicles [51] through actin ﬁlament
reorganization and membrane blebbing [51, 52], conceiv-
ably providing a mechanism whereby MAPKs can mediate
increased microglial proinﬂammatory cytokine release.
4. P2X7 Receptors and
Neurological/PsychiatricDiseases
4.1. Neurodegenerative Disorders. P2X7 receptors may aﬀect
neuronal cell death through their ability to regulate theCardiovascular Psychiatry and Neurology 5
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Figure 4: P2X7 receptor activation injures cortical neurons in vitro. Cocultures of rat cortical neurons and microglia were incubated for
3d a y s± 100 μM2  ,3  -O-(4-benzoyl-benzoyl)ATP (BzATP) ± 3μM Brilliant Blue G (Blue G). Labeling for the neuron-speciﬁc marker
βIII-tubulin showed neurons to survive well and elaborate extensive neurite networks in cultures with unstimulated microglia (a), whereas
BzATP caused a drastic and neuron-selective degeneration (b) that the P2X7 receptor antagonist Brilliant Blue G (c) prevented. Reproduced
from Skaper et al. [57], with permission from Wiley-Liss, Inc.
processing and release of IL-1β, a key mediator in neu-
rodegeneration [53]. Deletion of the P2X7 receptor did not
aﬀect neuronal cell death induced by transient or permanent
middle cerebral artery occlusion or by excitotoxic injury
[54]. In another study, organotypic mouse hippocampal
slice cultures were incubated for 3 hours to LPS, followed
by a 3-hour coincubation with ATP or a P2X7 receptor
agonist. A pronounced activation and apoptotic-like death
of microglia was associated with a massive release of IL-
1β, together with exacerbated CA3 pyramidal cell loss
inducedbysubsequentexposuretotheglutamatergicagonist
α-amino-3-hydroxyl-5-methyl-4-isoxazole propionate in an
IL-1β-dependent manner [55]. In rats subjected to spinal
cord injury, areas surrounding the traumatic lesion dis-
played an abnormally high and sustained pattern of ATP
release, and delivery of P2X7 antagonist after acute impact
injury improved functional recovery and diminished cell
death in the peritraumatic zone [56]. Acute spinal cord
injuries produce highly inﬂammatory environments [11],
and P2X7 receptor activation of local microglial cells may
have adverse eﬀects for neighboring neuronal cells. P2X7
may be involved in the generation of H2O2 in rat primary
microglia [37, 57]. P2X7 receptor-like immunoreactivity
was upregulated around β-amyloid plaques in Tg2576
mice (which overexpress the human amyloid precursor
protein harboring the Swedish familial mutation (K670→
N, M671→L)) and was regionally localized with activated
microglia and astrocytes [37]. Upregulation of the P2X7
receptor subtype on microglia has been observed also after
ischemia in the cerebral cortex of rats [58], and previous
work has demonstrated immunoreactivity for the P2X7
receptor on reactive astrocytes in multiple sclerosis autopsy
brain tissue [33].
Whether P2X7 receptor over-expression is driving
microglial activation or, conversely, P2X7 receptor over-
expression is a consequence of microglial activation is
not known. Using cocultures of rat cortical neurons and
microglia, Skaper et al. [57] have recently shown that ATP
and BzATP cause neuronal cell injury. Treatment with the
selective P2X7 antagonist Brilliant Blue G prevented the
deleterious eﬀects of BzATP-treated microglia (Figure 4).
Neuronal cell injury was attenuated by a superoxide dismu-
tase mimetic and by a peroxynitrite decomposition catalyst,
suggesting a role for reactive oxide species [57]. Cocultures
composed of wild-type cortical neurons and microglia from
P2X7 receptor-deﬁcient mice failed to exhibit neuronal cell
injury in the presence of BzATP but retained sensitivity
to injury when microglia were derived from genotypically
matched normal (P2X7
+/+ mice) [57]. P2X7 receptor activa-
tion on microglia thus appears necessary for microglial cell–
mediated injury of neurons.
A marked decline of intracellular ATP levels with a
concomitant eﬄux of ATP into the extracellular space occurs
in the rat brain during the ﬁrst few minutes after oxygen
depletion in vivo [59], and low concentrations of ATP can
act as a chemoattractant for microglia [60], directing them
to a site of injury. ATP released from activated astrocytes
activates microglia [61], and microglial cells could encounter
high levels of ATP near dying and disintegrating cells.
These observations indicate that ATP and ATP analogues do
act via the P2X7 receptor on microglia to aﬀect neuronal
cell health and that the P2X7 receptor can serve as an
important component of a neuroinﬂammatory response
(Figure 5(a)). Receptor antagonists of the P2X7 receptor
could have therapeutic utility in the treatment of AD and
cerebral ischemia and neuroinﬂammatory conditions by
regulating pathologically activated glial cells.
4.2. Pain. ATP is recognized as one of the keys for the relay
of sensory information from the periphery to the CNS [62],
and is also one of several important mediators involved in6 Cardiovascular Psychiatry and Neurology
immune-neural interactions [63]. Both sensory neurons and
glial cells inside and outside of the CNS release ATP to
aﬀect surrounding cells [64, 65]. Particularly intriguing is
the gathering body of literature linking activated microglia
and astrocytes to central sensitization and the development
and maintenance of neuropathic pain [65–67]. Both the
localization of P2X7 receptors on pro-inﬂammatory cells,
and the fact that ATP acting at P2X7 receptors serves as an
eﬃcient secondary stimulus for the generation and release
of IL-1β from proinﬂammatory cells [68] have implicated
ar o l ef o rP 2 X 7 receptors in inﬂammatory diseases [13]
(Figure 5(a)).
Labasi et al. [35] observed a lower incidence and severity
of monoclonal anticollagen-induced arthritis in P2X7 recep-
tor knockout mice compared with wild-type, suggesting
a pathological role for P2X7 receptors in inﬂammatory-
/immune-mediated disease. Deletion of the P2X7 gene
abolished the ability of ATP to induce IL-1β release from
macrophages isolated from these mice [34]. Local admin-
istration of a P2X7 receptor antagonist had antihyperal-
gesic eﬀects in the complete Freund’s adjuvant-induced
mechanical hyperalgesia (paw pressure) model [69]. More
recently, Chessell et al. [36] demonstrated that in mice
lacking the P2X7 receptor, inﬂammatory and neuropathic
hypersensitivity is completely absent to both mechanical
and thermal stimuli, while normal nociceptive processing
is preserved. In these knockout animals, systemic cytokine
analysis showed reductions in adjuvant-induced increases
in IL-1β, IL-6, IL-10, and macrophage chemoattractant
protein-1. Moreover, P2X7 receptor was upregulated in
human dorsal root ganglia and injured nerves obtained
from chronic neuropathic pain patients [36]. Endogenous
IL-1 levels are increased in the nervous system in response
to trauma associated with mechanical damage, ischemia,
seizures, and hyperexcitability [70]. At the level of the
spinal cord, blockage of IL-1 receptors results in reduced
nociception in animal models of inﬂammation and nerve
injury-induced pain [71, 72].
Much recent research has focused on the development
of novel, selective, and potent small molecule inhibitors
of the P2X7 receptor [73–77]. A-740003 and A-438079 are
structurally unrelated P2X7 antagonists, and both exhibit
therapeuticeﬃcacyonneuropathy-inducedmechanicalallo-
dynia [78, 79]. A-740003 also has antihyperalgesic eﬀects in
thecarrageenan-andadjuvant-inducedthermalhyperalgesia
models of inﬂammatory pain [78]. These data are consistent
with a study of an adamantane P2X7 antagonist (AACBA;
GSK314181A) that is structurally dissimilar from A-740003
and A-438079, which showed dose-dependent antinocicep-
tion in an inﬂammatory pain model [80]. The preclinical
testing of P2X7 antagonists strongly suggests therapeutic
potential in pathological pain and inﬂammation.
4.3. Depression. Intriguingly, cytokines like IL-1β are sug-
gested to be involved in the pathophysiology of depression.
This neuropsychiatric disorder is recognized as having high
prevalence in several clinical settings including infectious,
autoimmune, and neurodegenerative disorders, conditions
associated with a proinﬂammatory status, and it has been
proposed that excessive secretion of macrophage cytokines,
for example, IL-1β,T N F - α,a n dI F N - γ, could be a potential
causative factor [81]. Central and systemic administration of
proinﬂammatory cytokines (IL-1β,T N F - α, IL-6) to animals
induces what has been described as “sickness behavior,”
which is characterized by many of the physiological and
behavioral changes associated with depression [82, 83].
A similarity and functional linkage between symptoms of
sickness behavior in animals and those of depression in
humans has been suggested [83]. In addition, cytokines
can induce neuroendocrine and neurochemical changes
akin to a depressive syndrome [84], and clinical use of
cytokines (e.g., IFN-α) produces depressive-like symptoms
that can be attenuated with antidepressant treatment [85].
Not only do patients suﬀering from major depression,
who are otherwise medically healthy, often have signiﬁcant
elevations in the density of microglia [86] and elevated levels
of circulating proinﬂammatory cytokines [87–89] but also
mice lacking functional type 1 or type 2 TNF-α receptors
display an antidepressant phenotype [90]. Cytokines may
thus be involved in the etiopathogenesis of depression
(Figure 5(a)).
Linkage studies have shown that the P2X7 gene may
be involved in some neuropsychiatric conditions. Genetic
analysis of a French population indicated a Gln640Arg single
nucleotide polymorphism of the P2X7 receptor gene as a
potential susceptibility gene for bipolar eﬀective disorder
[91] and major depression [92, 93]. This Gln640Arg poly-
morphism is located at the C-terminal domain of the P2X7
receptor, which is essential forits normal function. Identiﬁed
polymorphisms in the P2X7 receptor of lymphocytes are
known to produce a loss of function or to alter traﬃcking
of the receptor to the membrane surface, thus decreasing its
membrane expression [94]. The functional consequences for
cytokine release of polymorphisms in the P2X7 receptor have
been investigated in some cases, which result in reduction
in TNF-α release from LPS stimulated leukocytes in the
presenceofATP[95].Bassoetal.[96]haverecentlydescribed
the behavioral proﬁle of P2X7 receptor gene knockout mice
in animal models of depression and anxiety, and found
an antidepressant-like phenotype together with a higher
responsiveness to a subeﬃcacious dose of the antidepressant
imipramine. Further research will be necessary to elucidate
thespeciﬁcmechanism(s)underlyingtheantidepressant-like
characteristics of P2X7 receptor knockout genotype and how
inactivation of the P2X7 gene is physiologically translated
into the expression of this behavioral proﬁle.
Activation of the inﬂammatory response in the etiology
of depression would lead one to predict that antidepres-
sant drugs display negative immunoregulatory eﬀects [97].
Indeed, a number of antidepressants that exhibit distinct
mechanisms of action, at therapeutically eﬀective concentra-
tions, limit the release of proinﬂammatory cytokines both
in vitro [98] and in vivo [99, 100]. In addition, antidepres-
sants attenuate the behavioral and emotional disturbances
elicited by immunostimulation and cytokine administra-
tion to humans and rodents [86, 100] and the abnormal
increased production of proinﬂammatory cytokines seen inCardiovascular Psychiatry and Neurology 7
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Figure 5: Schematic representation of the conditions which can lead to P2X7 receptor (P2X7R) activation in the nervous (a) and
cardiovascular (b) systems. Tissue trauma, stress, mechanical injury, infection, and autoimmune disorders, among others, can lead to
increased extracellular levels of ATP and/or proinﬂammatory cytokines. Extracellular ATP diﬀuses to activate neighboring cells by paracrine
and autocrine pathways. In this context signaling through the P2X7 receptor may allow cells to sense and respond to events occurring in
the extracellular environment, modulate the transcription of genes involved in cellular inﬂammatory processes, and thus regulate cytokine
responses. The P2X7 receptor may function as an ampliﬁcation device to spread the ATP wave as its activation triggers further ATP (and
proinﬂammatory mediator) release, culminating in pathology. These characteristics, coupled with the broad distribution of P2X7 receptors
encourage the therapeutic exploitation of this target. AD Alzheimer’s disease.8 Cardiovascular Psychiatry and Neurology
depressed patients [89, 101]. Antagonism of P2X7 receptors
may thus constitute a novel target for the treatment of
depression.
5. P2X7 ReceptorsandCardiovascularDisease
ATP is an important neurotransmitter being released with
noradrenaline andneuropeptide Yfromperivascularsympa-
thetic nerves; it acts at postjunctional P2X receptors to evoke
vascular smooth muscle contraction. The relative contribu-
tions of ATP and noradrenaline as functional cotransmitters
varies with species, age, type, and size of blood vessel, the
tone/pressure of the blood vessel, and in disease [102]. In
the vascular system, short-term purinergic signaling events
are associated with the control of blood vessel tone/pressure
inﬂuencedbyATPreleasedfromperivascularnerves,smooth
muscle, and endothelial cells [102, 103]. In the rat vascular
system, P2X7 receptor immunoreactivity was detected in all
arteries, with the exception of small renal arteries [104]. In
general, P2X7 receptor-speciﬁc immunoreactivity was seen
in the outer adventitial layer with a predominantly vesicular
distribution.Inthelargecoronaryandcerebralarteries,weak
diﬀuse P2X7 receptor immunoreactivity was also detected in
the smooth muscle layer [104]. P2X7 receptors are involved
in sympathetic nerve-mediated vasoconstriction in small
arteries of the rat hepatic mesentery [105]. Smooth muscle
layers of placental and umbilical blood vessels express func-
tional P2X7 receptors [106], suggesting their participation
in the humoral regulation of placental blood ﬂow. This is
novel,sincetheumbilicalcordlackssympatheticinnervation
[107], a documented source of ATP. In addition, ATP is
capable of increasing contractile tension in cardiac tissue via
P2X receptors [108], although the receptor subtype was not
identiﬁed.WhileATPcanalsoinducevasodilationinisolated
aortic preparations, the nature of the purinergic receptor site
responsible was not characterized [109–111].
Apoptotic cell death is recognized to occur in a number
of vascular diseases, including atherosclerosis, restenosis,
and hypertension [112, 113]. Vascular endothelial cells are
continuously exposed to variations in blood ﬂow, and
the shear stress that occurs during changes in blood ﬂow
causes a substantial release of ATP from endothelial cells
[114], which might mediate alterations in the balance
between proliferation and apoptosis [115]. Occupancy of
P2X7 receptors leads to the production of proinﬂammatory
cytokines, and TNF-α promotes endothelial cell apoptosis
via the activation of caspase 3 [113] which, conceivably,
play a role in vascular remodeling in hypertension [116].
Stimulation of P2X7 receptors on human dendritic cells
induces the release of tissue factor-bearing microparticles
[117], which may have implications for triggering and
propagating coagulation either in healthy or atherosclerotic
vessels. P2X7 receptor activation reportedly ampliﬁes LPS-
induced vascular hyporeactivity, due to IL-1β release from
endothelial cells, in turn inducing downstream nitric oxide
production [118]. Thus, the P2X7 receptor may be an
important regulator for vascular hypotensive responses in
inﬂammation or inﬂammatory-related disease (Figure 5(b)).
Intriguingly, evidence suggests that ambulatory blood pres-
sure is associated with polymorphic variation in the P2X7
receptor gene [119].
Incutaneousvesselswherepurinergicneurotransmission
is more prominent compared with deep vessels, physio-
logical and pathological roles of nerve-released ATP have
been described [120]. P2X7 receptors expressed in human
saphenous vein myocytes contribute to the contractile eﬀect
of ATP [121], and venous diseases may oﬀer conditions
allowing P2X7 receptor activation to cause lysis of venous
myocytes. ATP released after hypoxia, stress, and inﬂam-
mation, or membrane damage, conditions found in the
vessel wall of varicose veins [122], as well as that generated
by reduced ecto-ATPase activity [123], may lead to P2X7
receptor-induced pore formation, the disorganization and
loss of contractile myocytes in the muscle layers of the media
of varicose veins, and venous disease.
It is well established that both ATP and noradrenaline
are coreleased from sympathetic nerve varicosities [124].
Although in a range of muscular arteries both neurotrans-
mitters contribute to neurally evoked contraction [125],
ATP is the predominant sympathetic neurotransmitter in
rat mesenteric arteries at high intraluminal pressure [126].
The increased responses produced by ATP at higher pres-
sures could contribute to or exacerbate the raised pressure
observed in hypertension.
Fibroblasts are a key structural element of the arterial
wall, major producers of extracellular matrix, and an active
source of inﬂammatory mediators [127, 128]. In human
pathology, ﬁbroblast dysfunction is implicated in chronic
degenerative diseases such as atherosclerosis and diabetic
angiopathy [129]. In the atheromatous lesion, ﬁbroblasts
are a source of mediators that stimulate endothelial cells
and promote recruitment of leukocytes, thus accelerating
damage of the arterial intima and media [127]. In dia-
betes, the arterial wall undergoes accelerated degenerative
changes [130], the pathogenesis of which is incompletely
understood but that undoubtedly implicates profound
modiﬁcations of ﬁbroblast reactivity. In diabetic patients,
ﬁbroblast responses might be inherently aberrant [131],
thus rendering these cells sensitive to inﬂammatory factors
released into the blood or the arterial wall. It is likely
that ATP is released at the site of atherosclerotic lesions
or during platelet adhesion to the endothelium [132].
It is interesting to note a recent study demonstrating
that ﬁbroblasts from type-2 diabetes patients are char-
acterized by a hyperactive purinergic loop based either
on a higher level of ATP release or an enhanced P2X7
receptor reactivity, together with an increased pericellu-
lar concentration of ATP, and a higher basal level of
ﬁbronectin secretion and spontaneous rate of apoptosis at
least in part dependent on autocrine stimulation of P2X7
receptors by secreted ATP [133]( Figure 5(b)). Accumula-
tion of ﬁbronectin in the interstitial space (e.g., arterial
wall) in diabetes is believed to play a major role in the
pathogenesis of diabetic tissue damage [134]. In another
report, P2X7 receptor activation in diabetic rabbits led to
a marked reduction in retinal blood velocity and function
[135].Cardiovascular Psychiatry and Neurology 9
6. Concluding Remarks
It is now generally accepted that high levels of extra-
cellular nucleotides such as ATP may be released under
pathological conditions such as inﬂammation, trauma, and
stress. Interestingly, a number of neurodegenerative con-
ditions exhibit enhanced P2X7 receptor expression in the
neuroinﬂammatory loci where activated microglia are a
coexisting feature. Recent ﬁndings suggest that increased
P2X7 receptor numbers drive microglial activation, rather
than P2X7 receptor over-expression being a consequence of
microglialactivation[136].SignalingviaP2X7 receptors may
thus allow cells to sense and respond to events occurring
in the extracellular environment, modulate the transcription
of genes involved in cellular inﬂammatory processes, and
to thus regulate cytokine responses. Given the distribution
of P2X7 receptors and the fact that high concentrations
of ATP are required to activate the receptor, this P2X
receptor may be viewed as a ‘danger’ sensor. The therapeutic
exploitation of P2X7 r e c e p t o r si sn o wu n d e rw a yb e c a u s e
of their potential role, not only in such disorders as AD,
spinal cord injury, and sensory neuropathies [137] but also
in multiple sclerosis [138], inﬂammatory neuropathic pain
[36], rheumatoid arthritis [35], as well as depressive illness.
The discovery of P2X7 receptor-selective antagonists has
provided data demonstrating that the acute blockage of
P2X7 receptors signiﬁcantly reduces nociception in animal
models of persistent neuropathic and inﬂammatory pain,
while there is growing appreciation for the role of P2X7
receptor modulation of proinﬂammatory IL-1β processing
[139], the analgesic activity of P2X7 receptor antagonists
[78, 79] indicates a speciﬁc role for P2X7 receptors in
neuronal-glial cell interactions associated with ongoing pain
[23]. P2X7 receptors are expressed with some selectivity on
diﬀerent types of cells in the cardiovascular system, and
drugs aﬀecting P2X7 receptor signaling may have promise
as clinical antihypertensive and antithrombotic agents [140].
In this context, the P2X7 r e c e p t o rm a yb ev i e w e da sak e y
point of communication between the nervous, immune, and
cardiovascular systems. Further investigation of the P2X7
receptor with receptor subselective antagonists in preclinical
studies as well as in disease-speciﬁc clinical trials will help to
evaluate this target’s potential therapeutic use.
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